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Abstract
Introduction The disease activity in patients with rheumatoid
arthritis has improved during the past decade. The availability of
new drugs and also a better assessment of the disease have
been proposed to be responsible for this improvement. In the
present work we estimate the effect of these factors on disease
activity and function in patients with rheumatoid arthritis at the
beginning of the new century.
Methods The Estudio de la Morbilidad y Expresión Clínica de la
Artritis Reumatoide (EMECAR) cohort was assembled in 2000
from the random sampling of rheumatoid arthritis patients
registered in 34 centers. The cohort was composed of 789
patients who underwent a baseline assessment plus four annual
follow-up visits in which functional ability (Health Assessment
Questionnaire score), the disease activity score obtained from
28-joint count with three parameters (DAS28-3) and
radiological progression (Larsen score) were recorded. The
effect of the calendar year on the DAS28-3, the Health
Assessment Questionnaire score, and the Larsen score was
obtained from adjusted models in which all treatments were
included as dummy variables.
Results The effect of time as the β coefficient (95% confidence
interval) for 2004, taking 2000 as a reference year, was -0.43 (-
0.58 to -0.28) for the DAS28-3, 0.15 (0.07 to 0.22) for the
Health Assessment Questionnaire score, and 4.4 (2.68 to 6.12)
for the Larsen score. Treatment with new therapies, either
leflunomide or TNF antagonists, increased in frequency from
1.1% (n = 8) in 2000 to 30.9% (n = 144) in 2004. Treatment
with TNF antagonists (-0.28 (-0.5 to -0.05)) and with gold salts
(-0.21 (-0.38 to -0.04)) was independently associated with a
decrease in the DAS28-3 over time, whereas cyclosporin A
treatment (0.45 (0.13 to 0.76)) was associated with an increase
in disease activity.
Conclusions The mean disease activity of rheumatoid arthritis
has improved from 2000 to 2004. An explanation is the
introduction of new therapies, but not solely. Other factors
related to the calendar year, plausibly a better management of
available drugs, show a greater effect on improvement than the
drugs used.
Introduction
During the past decade, the number of therapeutic alternatives
against rheumatoid arthritis (RA) has gratifyingly increased.
Most of these new drugs belong to the so-called biologic
agents, which have been developed against specific targets
that play important functions in the pathogenesis of RA –
namely, TNF, IL-1, CTLA-4, and CD20. Leflunomide (LEF) was
introduced also in the past decade as a new nonbiologic dis-
ease-modifying antirheumatic drug (DMARD). TNF antago-
nists (aTNF) and LEF have demonstrated efficacy in
randomized controlled trials, not only improving disease activ-
ity but also decelerating or arresting radiological damage
[1,2]. When used outside trials, however, the effectiveness of
new drugs may differ, since patients included in clinical trials
are younger on average, have less comorbidity, and show
greater disease activity than real-life patients [3]. In addition,
aTNF: TNF antagonists; DAS28-3: disease activity score obtained from 28-joint count calculated using the formula with three parameters; DMARD: 
disease-modifying antirheumatic drug; EMECAR: Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide; HAQ: Health Assessment 
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drugs are prescribed according to strict protocols in clinical
trials, while routine prescription is based not only on character-
istics of the patients but also on physician's preferences [4,5].
While testing the hypothesis of a lower effectiveness of
DMARDs and biologic agents in observational studies com-
pared with clinical trials, we found that new drugs may have an
impact – benefiting not only patients who are exposed to them,
but also the nonexposed patients. The Estudio de la Morbili-
dad y Expresión Clínica de la Artritis Reumatoide (EMECAR)
cohort was assembled before the widespread use of LEF and
aTNF in Spain, during 1999 and 2000, and followed thereafter
for four consecutive years [4], thus providing an adequate sce-
nario to test hypothesis on new drugs. The present work
describes what happened to RA patients followed up routinely
in daily practice in terms of disease activity, disability and radi-
ological progression in the time when LEF and aTNF were
introduced.
Materials and methods
The EMECAR cohort study has been previously described in
detail [4,6]. The patient sample was formerly proven to ade-
quately represent RA patients attending rheumatology tertiary
hospitals in Spain, not very different from the mean RA patient
followed up elsewhere [4,6].
Sampling, recruitment, and data collection
All rheumatology clinics in Spain were invited to participate in
EMECAR. Out of a total of 176 centers registered at the
Sociedad Española de Reumatología database, 34 centers
volunteered for participation (see Additional file 1). Partici-
pants had to send a file listing all patients ever registered at
their clinics with a diagnosis of RA. Patients were randomly
selected from these local databases, after checking for dupli-
cates between centers. The selection complied with the Span-
ish regulations for Data Protection.
Participating rheumatologists were instructed to first confirm,
on viewing the clinical records, the patients selected fulfilled
the American College of Rheumatology 1987 criteria for the
classification of RA [7]. Secondly, rheumatologists had to fol-
low a contacting protocol that included three telephone calls
on different days and at different hours, a search in mortality
registries, and a letter to the address recorded in the database
if needed. If a patient could not be reached after this protocol
was followed, then the patient was discarded and replaced by
another patient randomly selected in the same center. If a con-
tacted patient did not want to enter the study, the patient was
asked a short questionnaire to assess the reason for refusal
and to determine basic sociodemographic and clinical charac-
teristics.
All patients who entered the cohort signed a written consent
form after being informed about the details of the study. The
study protocol was reviewed and approved by the Research
Ethics Committee of the Hospital Universitario de la Princesa,
and follows all present ethical principles in clinical research.
The baseline visit of the EMECAR cohort took place between
November 1999 and November 2000, although we will herein
refer to this visit as the reference year 2000. Thereafter, four
annual structured visits took place between 2001 and 2004
(see Additional file 2). The main objective of the cohort study
was to estimate the expression of RA as well as to estimate the
incidence of specific comorbidity in RA, and the prospective
data collection included sociodemographic, clinical, therapeu-
tic, laboratory, and radiological information. Participant rheu-
matologists were instructed to collect the data and were
trained in the performance of joint counts and other measure-
ments in a standardized fashion.
Data collected on DMARDs included their type, whether the
drug was currently in use or had been used during the previ-
ous year, and the reason for any discontinuation. All data were
obtained from the medical records and were confirmed with
the patient during the study visits. Patients went through a
complete physical examination and laboratory tests annually.
The disease activity score was obtained from 28-joint counts
using the formula with three parameters (DAS28-3) [8]. All
patients completed the Spanish version of the Health Assess-
ment Questionnaire (HAQ) to assess functional ability [9]. The
radiological damage was assessed in X-ray scans of the hands
and wrists biannually (2000, 2002, and 2004), which were
read centrally by a trained radiologist blinded to the patient's
record, and was scored by the Larsen method with the Scott
modification (range 0 to 150) [10]. The radiologist performed
an intraobserver reliability study on 20 randomized X-ray scans
in which the codes had been changed to avoid recall. The
intraclass correlation of the Larsen score between readings
was 0.94 (95% confidence interval = 0.82 to 1.00).
Although the EMECAR cohort is formed by 789 patients,
owing to different reasons we only have baseline values of the
DAS28-3 in 735 patients, of the HAQ score in 777 and of the
Larsen score in 678 patients. There were no relevant differ-
ences, however, in the characteristics of these patients with
missing values compared with those studied (see Additional
file 3).
Statistical analysis
Mean differences between groups at baseline regarding con-
tinuous and nonparametrically distributed variables were ana-
lyzed using Student's t test and the Mann–Whitney U test,
respectively. Association with categorical variables was tested
with chi-square tests or Fisher's exact tests.
To determine the effect of the different DMARDs on the pro-
gression of the DAS28-3, the HAQ score, and the Larsen
score we fitted a population-averaged model by weighted esti-
mating equations nested by patient and visit, using the com-Available online http://arthritis-research.com/content/10/6/R138
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mand  GENMOD  of SAS/STAT 8.2 for Windows (SAS
Institute Inc., Cary, NC, USA). Weighted estimating equations
are an extension of the generalized estimating equations in the
presence of missing visits. This method consists of creating
weights for each observation, at each time point, on the basis
of previous observations and informative covariates. The
weights represent the inverse probability of having dropped
out and are then incorporated into the generalized estimating
equations model. In our case, we used the fitted probabilities
of having dropped out from a logistic regression with visit, sex,
age and previous responses of the DAS28-3, the Larsen score
and the HAQ score as independent covariates [11]. Addition-
ally, patients with missing data were compared with the rest of
patients in the covariates included in the analyses.
We tried different working correlations [12], such as inde-
pendent, autoregressive (order 1), unstructured or exchange-
able. We finally chose exchangeable among these competing
correlation structures, using the smallest quasi-likelihood
under the independence model information criterion values
[13], measured in a bivariate analysis with year of visit as the
only predictor. Actually, all of the above structures yielded sim-
ilar results.
In addition to the calendar year and the DMARD prescription
at each visit (gold salts, antimalarial, methotrexate (MTX), LEF,
sulfasalazine cyclosporine A, aTNF and others), the following
covariates were also analyzed: age at disease onset, age at
baseline, gender, years of disease duration, presence of
comorbidity (hypertension, diabetes mellitus, peptic ulcer,
ischemic heart disease, heart failure, stroke, chronic obstruc-
tive pulmonary disease, neoplasms, liver disease, and depres-
sion), presence of any extra-articular manifestation (carpal
tunnel syndrome, secondary Sjögren's syndrome, serositis,
secondary clinical amyloidosis, rheumatoid vasculitis, eye dis-
ease, interstitial lung disease, rheumatoid nodules, Felty's syn-
drome, or anterior atlantoaxial luxation), rheumatoid factor
positivity, serum hemoglobin, alkaline phosphatase, body
mass index and the DAS28-3, the HAQ score and the Larsen
score at baseline.
Bivariate analysis was performed with all factors and covari-
ates, and then backward stepwise selection was applied in
multivariate weighted generalized estimating equation models,
starting with all variables that reached P < 0.2 in the bivariate
analysis. The final models were reached by means of the
quasi-likelihood information criterion [13] and we did not force
any variable into the models (that is, we discussed whether
gender should be included in models for the DAS28-3 but
found there was also some collinearity with other variables,
such as low hemoglobin).
In addition, we reran all analyses with the 448 patients
(57.6%) who attended all visits; there were no relevant differ-
ences with the results obtained from the whole population.
Results
Treatment patterns
Patients who used aTNF or LEF at any time during follow-up
were younger at baseline (2000), had an earlier RA onset, and
presented more active disease than those who never used
aTNF or LEF during follow-up (Table 1).
Few patients were on aTNF and LEF in 2000, and those
treated with them were either patients enrolled in clinical trials
or were using these drugs compassionately. During 2001,
both infliximab and LEF were authorized to be used in RA
patients in Spain. Later on, etanercept (2002) and adalimu-
Table 1
Baseline (2000) characteristics of the patients in EMECAR
Characteristic All studied patients Ever used aTNF or LEF Never used aTNF or LEF
n 789 210 (27%) 579 (73%)
Women 568 (72) 159 (76)* 409 (71)
Age (years) 61 ± 13 57 ± 12*** 63 ± 13
Age at rheumatoid arthritis onset (years) 48 ± 15 44 ± 13*** 50 ± 15
Rheumatoid factor-positive 592 (75) 167 (79)** 346 (70)
Any comorbidity 606 (77) 154 (73) 380 (77)
Any extra-articular rheumatoid arthritis 355 (45) 122 (58)* 226 (46)
Health Assessment Questionnaire score 1.2 ± 0.9 1.3 ± 0.8 1.2 ± 0.9
Disease activity score from 28-joint count with three parameters 4.1 ± 1.4 4.6 ± 1.4*** 3.9 ± 1.3
Larsen score 54 ± 27 57 ± 24 53 ± 27
Data presented as n (%) or as mean ± standard deviation. Characteristics of those patients who used TNF antagonists (aTNF) or leflunomide 
(LEF) at any time of follow-up were compared with those of patients who did not. ***P < 0.001, **P < 0.01, *P < 0.05.Arthritis Research & Therapy    Vol 10 No 6    González-Alvaro et al.
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mab (2003) were also marketed and approved, respectively.
The introduction of aTNF and LEF into the market clearly cor-
related with the number of prescriptions year by year, from
eight patients (1.8%) in 2000 to 143 patients (31.9%) in
2004 (Figure 1a). During 2004, 15.8% of patients were on an
aTNF and 19% received LEF. A p a r t  f r o m  M T X ,  w h i c h
remained in use in around 50% of the patients, all other
DMARDs experienced a decrease in their use over time, which
was particularly evident in the case of gold salts.
The proportion of patients with no DMARDs decreased during
follow-up, although not significantly (20%, 20%, 14%, 16%,
and 16%, annually from 2000 to 2004). Both the percentages
of patients on any DMARD monotherapy (from 57.8% to
59.8%, 2000 to 2004) or on combined therapy (from 22.6%
to 24.2%, 2000 to 2004) increased, although none signifi-
cantly. Of note, the drugs that were used in combination
clearly changed during follow-up. In 2000, the drugs most fre-
quently combined with MTX were antimalarials and gold salts,
followed by sulfasalazine and cyclosporine (Figure 1b, upper
panel). The scenario completely switched in 2004 towards
combination therapy including MTX plus LEF or MTX plus
aTNF (Figure 1b, lower panel).
We also observed that the combination of LEF and aTNF
increased to become the third most frequent combination
used in 2004 (Figure 1b, lower panel). Conversely, the most
frequent combinations in 2000 – MTX plus antimalarials or
MTX plus gold salts – became anecdotic in 2004. Triple ther-
apy, namely MTX plus sulfasalazine plus antimalarials, sup-
ported by evidence [14], was only used in four patients during
2000 and used in three patients in 2004.
Effect of time and treatment on disease
The median (interquartile range) of the DAS28-3 was 4.0 (3.0
to 5.1) in 2000, and this gradually decreased to 3.5 (2.7 to
4.6) in 2004. This decrease was also present when analyzing
the patients who were treated and who were nontreated with
Figure 1
Percentages of different systemic treatments and evolution of combination therapies Percentages of different systemic treatments and evolution of combination therapies. (a) Percentage of patients treated with each of the dif-
ferent systemic treatments, by year of follow-up. (b) Evolution of combination therapies used in the EMECAR cohort. Circle diameters are propor-
tional to the number of patients with the corresponding combination therapy, the smallest ones representing one patient (gold salts plus 
sulfasalazine in 2000) and the biggest circle representing 35 patients (methotrexate plus TNF antagonists in 2004).Available online http://arthritis-research.com/content/10/6/R138
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new therapies separately (Figure 2). The HAQ score wors-
ened slightly, from 1.125 (interquartile range = 0.50 to 1.875)
in 2000 to 1.25 (interquartile range = 0.50 to 1.875) in 2004.
The median Larsen score in hands was 48 (interquartile range
= 34 to 71) in 2000, and increased to 55 (interquartile range
= 37 to 70) in 2004.
To analyze the effect of time as well as the effect of each
DMARD separately on the DAS28-3, the HAQ score, and the
Larsen score over time, we first analyzed other predictors to
adjust for as covariates in the weighted estimating equations
models. The baseline DAS28-3 was associated with a signifi-
cant progression of DAS28-3 and Larsen score (Table 2). In
addition, extra-articular RA was also associated with higher
DAS28-3 values and, conversely, higher levels of serum hemo-
globin were associated with lower DAS28-3 values (Table 2).
The baseline Larsen score was associated with a higher
Larsen score during follow-up (Table 2). Being of an older age
and presenting an increased HAQ value at baseline were both
associated with worse progression of HAQ scores (Table 2).
Regarding the effect of DAS28-3 on the HAQ, at each visit
worse disease activity scores were associated with worse
HAQ scores (Table 2).
The effect of the calendar year on the DAS28-3, the HAQ
score, and the Larsen score was obtained from adjusted mod-
els in which all treatments were included as dummy variables.
The β coefficients and 95% confidence intervals during 2001
to 2004, taking 2000 as the reference year, are presented in
the lower panel of Table 2. Disease activity decreased signifi-
cantly compared with baseline year during follow-up.
The effect of individual DMARDs on disease activity, function,
and damage over time was evaluated by including dummy var-
iables for DMARDs in the final fitted models. Figure 3 shows
the effect of individual drugs on the DAS28-3, the HAQ score,
and Larsen score. As is shown in Figure 3 (upper panel), treat-
ment with aTNF (β coefficient = -0.28 (95% confidence inter-
val = -0.5 to -0.05), P <0.05) and with gold salts (β coefficient
= -0.21 (95% confidence interval = -0.38 to 0.04), P < 0.05)
was independently associated with a decrease in the disease
activity, whereas cyclosporin A treatment (β coefficient = 0.45,
95% confidence interval = 0.13 to 0.76), P < 0.01) was asso-
ciated with an increase in the DAS28-3 value. The remaining
DMARDs did not seem to affect the DAS28-3 significantly.
The whole effect of DMARDs on the HAQ score seemed to be
the prevention of disability impairment – LEF was the only drug
that tended to be associated with an improvement of this
measurement, although it did not reach statistical significance
(P = 0.073). Surprisingly, treatment with aTNF was associated
with a significant radiological progression (Larsen β coefficient
= 2.79 (95% confidence interval = 0.27 to 5.31), P < 0.05)
and cyclosporin A treatment was associated with a significant
improvement of this parameter (Larsen β coefficient = -1.51
(95% confidence interval = -2.8 to -0.23), P < 0.05).
Discussion
The management of RA has experienced relevant changes
during the past decade. The development of biologic thera-
pies, as well as the rigorous clinical trials that have demon-
strated their effectiveness, have probably contributed to this
change. The most relevant finding of our work is that disease
activity in RA has improved, independently of the availability of
Figure 2
Disease activity over time following treatment with new therapeutic agents or nontreatment Disease activity over time following treatment with new therapeutic agents or nontreatment. Disease activity, as measured by the disease 
activity score from 28-joint count with three parameters (DAS28-3), over time in patients treated or not treated with new therapeutic agents, 2000 to 
2004. LEF, leflunomide.Arthritis Research & Therapy    Vol 10 No 6    González-Alvaro et al.
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Table 2
Variables associated with the evolution of the disease activity score from 28-joint count with three parameters (DAS28-3), the 
Health Assessment Questionnaire (HAQ) score, and the Larsen score in the EMECAR cohort
DAS28-3 HAQ score Larsen score
Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate
Female gender 0.57 (0.36 to 
0.78)***
- 0.42 (0.29 to 
0.55)***
- 6.49 (1.53 to 
11.45)*
-
Age at baseline 0.001 
(-0.006 to 0.007)
- 0.004 (0 to 
0.008)*
0.002 (0 to 
0.004)*
-0.19 (-0.34 to -
0.03)*
0.009 
(-0.025 to 0.043)
Age at disease 
onset
0.006 
(-0.002 to 0.007)
0.002 
(-0.002 to 0.007)
0.20 (0.016 to 
0.024)***
- 0.57(0.42 to 0.73) -
Disease duration 0.004 
(-0.007 to 0.015)
- 0.017 (0.009 to 
0.024)***
- 0.94 (0.55 to 
1.34)***
-
Extra-articular 
rheumatoid 
arthritis
0.32 (0.15 to 
0.4)***
0.16 (0.04 to 
0.28)*
0.22 (0.13 to 
0.31)***
0.03 
(-0.02 to 0.09)
0.06 (6.35 to 
11.76)***
-
Rheumatoid factor 0.19 
(-0.03 to 0.41)
0.02 
(-0.12 to 0.16)
0.14 (0.01 to 
0.28)*
0.03 (-0.04 to 0.1) 7.96 (3.19 to 
12.72)**
0.71 
(-0.37 to 1.80)
Hemoglobin (g/dl) -0.29 (-0.34 to -
0.25)***
-0.19(-0.23 to -
0.15)***
-0.1 (-0.12 to -
0.07)***
-0.03 (-0.05 to -
0.01)**
-0.95 (-1.61 to -
0.28)**
-0.04 
(-0.32 to 0.25)
Hypertension 0.05 
(-0.11 to 0.21)
- 0.19 (0.11 to 
0.27)***
0.05 
(-0.01 to 0.11)
2.74 (0.4 to 
5.08)*
-0.34 
(-1.3 to 0.61)
Diabetes mellitus -0.01 
(-0.27 to 0.24)
- 0.07 
(-0.08 to 0.22)
- -1.87 
(-6.54 to 2.8)
-
Hyperlipidemia -0.14 
(-0.31 to 0.03)
0.08 
(-0.05 to 0.21)
-0.5 
(-0.14 to 0.04)
- -1.44 
(-4.71 to 1.84)
-
Peptic ulcer 0.17 
(-0.13 to 0.47)
- 0.15 (0.02 to 
0.28)*
0.05 
(-0.03 to 0.13)
1.30 
(-3.06 to 5.66)
-
Myocardial 
ischemia
-0.05 
(-0.33 to 0.23)
- 0.17 
(-0.08 to to0.42)
0.06 
(-0.09 to 0.21)
-0.49 
(-6.56 to 5.58)
-
Heart failure 0.31 (0.04 to 
0.59)*
0.06 
(-0.21 to 0.33)
0.36 (0.21 to 
0.50)***
- -0.74 
(-7.21 to 5.72)
-
Stroke 0.15 (-0.2 to 0.49) - 0.02 (-0.27 to 0.3) - -8.94 (-13.79 to -
4.09)***
-
Chronic 
obstructive 
pulmonary disease
-0.1 
(-0.38 to 0.17)
- 0.01 
(-0.13 to 0.14)
- 2.2 (-3.23 to 7.64) -
Neoplasm -0.29 
(-0.61 to 0.03)
- 0.01 
(-0.12 to 0.14)
- -1.96 
(-9.92 to 6.01)
-
Liver disease 0.11 (-0.1 to 0.33) - -0.2 
(-0.11 to 0.08)
- -3.63 
(-9.01 to 1.76)
-2.57 (-5.07 to -
0.07)*
Depression 0.27 (0.09 to 
0.46)**
0.12 
(-0.03 to 0.26)
0.15 (0.05 to 
0.25)**
0.02 
(-0.05 to 0.09)
-0.79 
(-3.61 to 2.03)
-
Body mass index 0 (-0.02 to 0.02) - 0.01 (0 to 0.02) 0 (-0.01 to 0) -0.78 (-1.16 to -
0.4)***
-0.16 
(-0.65 to 0.33)
DAS28-3 
(each visit)
- - 0.17 (0.15 to 
0.19)***
0.15 (0.13 to 
0.17)***
0.37 
(-0.23 to 0.98)
-
DAS28-3 
(baseline)
0.62 (0.57 to 
0.67)***
0.53 (0.48 to 
0.59)***
0.24 (0.2 to 
0.28)***
-0.1 (-0.13 to -
0.07)***
6.79 (5.42 to 
8.15)***
0.68 (0.26 to 
1.11)**
HAQ score 
(each visit)
----4 . 9 2  ( 3 . 6 1  t o  
6.24)***
-
HAQ score 
(baseline)
- - 0.85 (0.82 to 
0.88)***
0.82 (0.78 to 
0.86)***
--Available online http://arthritis-research.com/content/10/6/R138
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new therapies, in patients with severe disease, and also in
patients with milder forms of the disease. Our work also
proves that aTNF promote a significant improvement of RA
disease activity in daily clinical practice in a similar way to ran-
domized clinical trials. Disappointingly, we could not observe
the amazing halt of radiological progression described in clin-
ical trials.
Our data show that, once the effect of variables known to
affect these outcomes was removed – such as age, rheuma-
toid factor, RA complications, disease duration, and comorbid-
ity [15] – both disability and radiological progression
worsened less than expected over time. Furthermore, when
we included all DMARD treatments in the model, the effect of
the calendar year on activity, disability and damage remained
unchanged – thus reflecting a smaller effect of treatment than
of other unmeasured variables that improved with time.
Our hypothesis is that this improvement may be associated
with a more efficient management of RA by Spanish rheuma-
tologists based at tertiary centers. As a matter of fact, during
1998 and 1999 most Spanish RA patients were on MTX but
at insufficient doses [5] – the median of the highest MTX dose
ever prescribed being 10 mg/week (interquartile range = 7.5
to 12.5 mg/week) [16]. The DMARD dose was not collected
in EMECAR, but data from a national early RA register (Estu-
dio de los factores pronósticos de enfermedad grave en la
artritis reumatoide de reciente comienzo [Study of the prog-
nostic factors in early arthritis]) show that in 2001 the median
MTX dose was 7.5 mg/week (interquartile range = 7.5 – 12.5
mg/week) while in 2005 the median dose was 12.5 mg/week
(interquartile range = 10 to 15 mg/week) (unpublished data).
Two reasons may explain this change in the management of
MTX. First, 90% of all Spanish rheumatologists in 1998 and
1999 had never collected the variables needed to estimate the
DAS28-3 during daily clinical practice [17], therefore the sys-
tematic assessment of disease activity they had to perform per
protocol in EMECAR led the rheumatologists to realize the
poor control they had over their own patients. On the other
hand, the finding may also reflect the experience of rheumatol-
ogists in numerous aTNF clinical trials, where fast MTX dose
escalation was the norm [18,19].
Additional data support this change towards a more efficient
treatment of RA in Spain. Throughout the follow-up of the
EMECAR cohort, the percentage of patients without any
DMARD declined while the frequency of patients on combined
therapy increased. In addition, combination therapies with less
supporting evidence, such as MTX plus antimalarials or MTX
plus sulfasalazine [20], gradually disappeared as they were
replaced by more aggressive combinations with better proven
efficacy [18,19,21-25]. Finally, parallel to our findings, a more
effective DMARD use has been recently demonstrated as the
main reason for the decreasing progression of radiological
damage in patients with RA over time [26].
In addition, our study provides some interesting findings about
the result of gold salts and cyclosporin A prescriptions. We
have observed that patients treated with parenteral gold salts
showed a better DAS28-3 evolution together with an arrest in
the evolution of the HAQ and Larsen scores. This finding was
opposite to the impression of Spanish rheumatologists about
this drug, since inefficacy was the most frequent reason to
explain withdrawal of gold salts in EMECAR (see Additional
file 4). Patients on gold salts might had a more benign disease
course, however, and in the event they suffered a RA worsen-
ing or a flare up they were probably switched to another
DMARD, instead of using gold as an add-on therapy.
Regarding cyclosporin A treatment, it was surprising that pre-
scription of this drug was associated with the worst DAS28-3
evolution but, conversely, those patients displayed the best
radiological evolution. The reason for this contradictory finding
might be the well-known failure of cyclosporin A to improve the
Larsen score 
(baseline)
----0 . 9 7  ( 0 . 9 5  t o  
0.99)***
0.96 (0.94 to 
0.98)***
Year
 2000 Reference Reference Reference Reference Reference Reference
 2001 -0.3 (-0.4 to -
0.2)***
-0.23 (-0.33 to -
0.13)***
0.01 
(-0.03 to 0.05)
0.04 
(-0.02 to 0.09)
NA NA
 2002 -0.32 (-0.43 to -
0.21)***
-0.27 (-0.38 to -
0.15)***
0.06 (0.01 to 
0.11)*
0.07 (0.01 to 
0.13)*
2.09 (1.32 to 
2.86)***°
2.07 (1.1 to 
3.04)***
 2003 -0.47 (-0.58 to -
0.36)***
-0.4 (-0.53 to -
0.27)***
0.05 (0 to 0.11) 0.11 (0.04 to 
0.18)**
NA NA
 2004 -0.5 (-0.63 to -
0.37)***
-0.43 (-0.58 to -
0.28)***
0.09 (0.03 to 
0.15)**
0.15 
(0.07 to 0.22)
4.18 (2.68 to 
5.68)***
4.4 (2.68 to 
6.12)***
Data presented as β coefficient (95% confidence interval). NA, not available. ***P < 0.001, **P < 0.01, *P < 0.05.
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erythrocyte sedimentation rate [27,28]. Considering the large
effect of the erythrocyte sedimentation rate on the disease
activity score, the use of this score represents a handicap for
the evaluation of the efficacy of cyclosporin A on disease activ-
ity. On the other hand, cyclosporin A inhibits the synthesis of
IL-17 [29], which in turn promotes RANKL production. With
this background it is possible that cyclosporin A decreases the
RANKL/osteoprotegerin ratio and, therefore, can explain the
remarkable effect of this drug in radiological progression,
which has been also described by Jones and colleagues [30].
Regarding the impact of new therapies in RA, aTNF decreased
the DAS28 score by, on average, 0.3 points. In opposition to
the good concordance regarding the effect of aTNF on RA dis-
ease activity between data from clinical trials and our data from
daily clinical practice, radiological progression was signifi-
cantly worse in patients treated with these drugs. The most
feasible explanation to this finding is that our cohort comprises
mainly longstanding patients and aTNF were probably pre-
scribed to those with more severe disease and higher Larsen
scores at the beginning of the study (Table 1). In these condi-
tions, it has been described that articular damage can
progress in the absence of relevant disease activity [31].
Accordingly, with this disappointing radiological outcome in
daily clinical practice, Listing and colleagues have reported
that biologics provide higher remission rates than classical
DMARDs, although in both cases the percentage of patients
who reached this ideal state was very low [32]. In this regard,
it has been described that patients in daily clinical practice are
older and have more comorbidities than those included in clin-
ical trials [3]. These characteristics may hinder the optimiza-
tion of aTNF treatment and therefore may also underlie the
results obtained in our study, which are less impressive than
those reported in clinical trials. In addition, changes in tender
joint counts may be hard to detect in older patients, as well as
those with longer duration of disease. This may be due to the
presence of residual damage or osteoarthritis, both resulting in
low improvements in the disease activity score.
Considering all this information, we clearly need specific mark-
ers of RA severity that allow us to select adequate patients for
early biologic treatment in order to improve their therapeutic
response, as well as their functional outcome. These tools may
also help to improve the cost-effectiveness of these drugs,
avoiding unnecessary prescriptions.
Conclusion
Our work shows that the mean disease activity of RA at tertiary
hospitals in Spain has improved from 2000 to 2004. One
explanation is the introduction of new therapies, since we have
confirmed that the use of these drugs was associated with an
improvement of the average disease activity score and of the
HAQ score. Other factors related to the calendar year, how-
ever, show a greater effect than the drugs used on improve-
ment. It is probable that a better management of available
Figure 3
Treatment effects over time on disease activity, function and disease  progression Treatment effects over time on disease activity, function and dis-
ease progression. Effect over time of different treatments on disease 
activity score from 28-joint count with three parameters (DAS28-3), 
function (Health Assessment Questionnaire (HAQ)), and disease pro-
gression (Larsen score). Pikes and lines represent the estimated β 
coefficients and 95% confidence intervals in the weighted estimating 
equations, adjusted by covariates and calendar year (see Statistical 
analysis). *P < 0.05, **P < 0.01.Available online http://arthritis-research.com/content/10/6/R138
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drugs, mainly MTX, has been learnt during the past decade
along with the clinical development of most biologic agents,
during which MTX has been used in a fast dose-escalation
fashion. In addition, the systematic assessment of disease
activity required in the EMECAR follow-up may have helped
Spanish rheumatologists to realize that patients were not ade-
quately controlled, thus leading to enhancement of patients'
treatment.
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